National Institute for Clinical Excellence (NICE) guidelines on venous thromboembolic (VTE) prophylaxis for patients undergoing orthopaedic surgery recommend that all inpatients be offered a low molecular weight heparin (LMWH).

Linked hospital episode statistics of 219602 patients were examined to determine the rates of complications following lower limb arthroplasty for the 12-month periods prior to and following the publication of these guidelines. This was compared with data from the National Joint Register (England and Wales) regarding LMWH usage during the same periods.

There was a significant increase in the reported use of LMWH (59.5 to 67.6%, p< 0.01) between the two periods. However, 90-day VTE events increased following both total hip (THR, 1.67% to 1.84%, p=0.06) and knee replacement (TKR, 1.99% to 2.04%, p=0.60). 30-day return to theatre rate for infection fell following TKR, but increased after THR. In addition, there were increases in rates of thrombocytopenia, which was significant following THR (p=0.03).

Recommendations from NICE are based on predicted reductions in VTE events, reducing morbidity, mortality and costs to the National Health Service. Early results in orthopaedic patients are unable to support these predictions.